NCT02705352Source recordAI-normalized
A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts.
The clinical trial sponsored by Massachusetts Eye and Ear Infirmary aims to evaluate the efficacy of 5-fluorouracil (5-FU) in reducing complications associated with periocular full thickness skin grafts. Given the limited options for managing scarring and graft shrinkage in oculofacial surgery, a successful outcome could position 5-FU as a novel adjunct therapy in this niche market. The potential to enhance patient satisfaction and reduce the need for corrective surgeries could lead to significant adoption among ophthalmic surgeons. However, challenges in patient recruitment may hinder the trial's robustness and subsequent market entry. Competitive analysis reveals that while corticosteroids are currently the standard treatment, 5-FU could offer a safer alternative with fewer side effects, particularly in sensitive periocular applications.
AI analysis
Indication: Ectropion
Modality: small molecule
Target: Thymidylate synthetase (inhibition by 5-fluorouracil)
Sponsor: Massachusetts Eye and Ear Infirmary
Source URL: ClinicalTrials.gov
Source updated: Mar 09, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Ectropion, Skin Neoplasms
Condition normalized: Ectropion, Skin Neoplasms
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Thymidylate synthetase (inhibition by 5-fluorouracil)
Target normalized: Thymidylate synthetase (inhibition by 5-fluorouracil)
NCT06100887Source recordAI-normalized
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Edgewise Therapeutics is advancing EDG-5506 through a Phase 2 study (FOX) aimed at assessing its safety and efficacy in children and adolescents with Duchenne muscular dystrophy (DMD) who have previously received gene therapy. The study's design includes a randomized, double-blind, placebo-controlled phase followed by an open-label extension, which may provide robust data on long-term safety and efficacy. Given the unmet medical need in DMD and the increasing focus on gene therapy, successful outcomes could position Edgewise favorably in a competitive landscape that includes established players in the DMD space. The market for DMD therapies is expanding, with a growing number of gene therapies and supportive treatments, indicating potential for significant commercial opportunity if EDG-5506 demonstrates positive results.
AI analysis
Indication: Duchenne Muscular Dystrophy
Modality: small molecule
Target: Sevasemten (EDG-5506) targets muscle damage biomarkers in Duchenne muscular dystrophy (DMD) patients, potentially modulating muscle regeneration and function.
Sponsor: Edgewise Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Nov 06, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Duchenne Muscular Dystrophy
Condition normalized: Duchenne Muscular Dystrophy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Sevasemten (EDG-5506) targets muscle damage biomarkers in Duchenne muscular dystrophy (DMD) patients, potentially modulating muscle regeneration and function.
Target normalized: Sevasemten (EDG-5506) targets muscle damage biomarkers in Duchenne muscular dystrophy (DMD) patients, potentially modulating muscle regeneration and function.
NCT04611711Source recordAI-normalized
An Evaluation of the Effectiveness and Safety of Decitabine Combined With TQB2450 Injection (PD-L1 Monoclonal Antibody) or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors I /Phase II Clinical Study
This clinical trial, sponsored by Peking University, aims to evaluate the effectiveness and safety of a combination therapy involving decitabine, TQB2450 (a PD-L1 monoclonal antibody), and anlotinib in patients with digestive system tumors that have shown resistance to PD-1 inhibitors. The market for cancer therapies, particularly those targeting immune resistance mechanisms, is rapidly expanding, with significant competition from existing PD-1/PD-L1 inhibitors and emerging combination therapies. Successful outcomes could position the sponsor favorably within this competitive landscape, particularly if they demonstrate improved efficacy in a patient population with limited treatment options. Diligence should focus on the trial's recruitment status and the regulatory pathway for TQB2450, as well as potential partnerships for commercialization.
AI analysis
Indication: Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
Modality: small molecule
Target: PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.
Sponsor: Peking University
Source URL: ClinicalTrials.gov
Source updated: Nov 02, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
Condition normalized: Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.
Target normalized: PD-L1 (Programmed Death-Ligand 1), with additional focus on epigenetic modulation via decitabine and angiogenesis inhibition via anlotinib.
NCT05926336Source recordAI-normalized
To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Brain, Liver, Lung, and Ovarian Cancer Tumors and the Investigation of Its Mechanism of Action
This clinical trial, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital, is currently recruiting participants and aims to elucidate the impact of different anesthetic techniques on cancer surgery outcomes. The findings could have significant implications for clinical practice in anesthesiology and oncology, potentially influencing anesthetic protocols in surgical oncology. Given the high incidence of these cancers, successful outcomes may enhance the market positioning of the involved anesthetics and lead to increased adoption in surgical settings. The trial's results could also inform future product development and marketing strategies for anesthetic agents, particularly in the context of cancer care.
AI analysis
Indication: Lung Cancer
Modality: small molecule
Target: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Source URL: ClinicalTrials.gov
Source updated: Sep 28, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Lung Cancer, Brain Tumor, Liver Cancer, Ovarian Cancer
Condition normalized: Lung Cancer, Brain Tumor, Liver Cancer, Ovarian Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
Target normalized: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
NCT00066092Source recordAI-normalized
Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.
This clinical trial, sponsored by Amgen, evaluates the efficacy and safety of pegfilgrastim compared to filgrastim for PBPC mobilization in patients with Hodgkin's and non-Hodgkin's lymphoma. Given the established market for G-CSF products, including filgrastim, pegfilgrastim's longer-acting formulation may provide a competitive advantage in terms of patient compliance and treatment convenience. The trial's completion in 2004 positions Amgen to leverage potential market exclusivity and enhance its portfolio in hematology and oncology, particularly in the context of autologous stem cell transplantation. The results could influence treatment guidelines and establish pegfilgrastim as a preferred option, impacting market dynamics and competitive positioning.
AI analysis
Indication: Lymphoma
Modality: small molecule
Target: Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Feb 28, 2008
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology
Condition normalized: Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).
Target normalized: Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).
NCT03194009Source recordAI-normalized
Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.
The PRuDENTE initiative, sponsored by the Instituto Nacional de Salud Publica in Mexico, aims to evaluate the cost-effectiveness of metformin combined with lifestyle modifications in preventing type 2 diabetes among pre-diabetic adults with obesity. Given the high prevalence of diabetes in Mexico, this study addresses a significant public health challenge and has the potential to inform national healthcare policies. If successful, the findings could lead to broader adoption of metformin as a preventive measure, impacting the pharmaceutical market for diabetes medications and lifestyle interventions. The study's outcomes may also attract interest from healthcare providers and insurers focused on cost-effective diabetes prevention strategies.
AI analysis
Indication: Diabetes Mellitus, Type 2
Modality: small molecule
Target: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.
Sponsor: Instituto Nacional de Salud Publica, Mexico
Source URL: ClinicalTrials.gov
Source updated: Mar 07, 2018
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Diabetes Mellitus, Type 2, Prediabetic State
Condition normalized: Diabetes Mellitus, Type 2, Prediabetic State
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.
Target normalized: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.
NCT00658411Source recordAI-normalized
A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload
The pilot study sponsored by Dana-Farber Cancer Institute aimed to evaluate the safety and feasibility of deferoxamine in patients with myelodysplastic syndromes or acute leukemia undergoing stem cell transplantation. The study was terminated due to slow patient accrual, indicating potential challenges in recruitment for future studies. The market for iron chelation therapy is significant, particularly in hematological malignancies, but the competitive landscape includes established therapies and emerging novel agents. The limited patient enrollment raises concerns about the viability of further development without robust data supporting efficacy and safety.
AI analysis
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.
Sponsor: Dana-Farber Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Apr 09, 2013
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Condition normalized: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.
Target normalized: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.
NCT00079378Source recordAI-normalized
A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies
The Phase I study of Decitabine in combination with Valproic Acid is sponsored by the National Cancer Institute and focuses on patients with refractory or relapsed acute myeloid leukemia (AML) and previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The combination therapy aims to improve treatment outcomes by leveraging the distinct mechanisms of action of both agents. Given the high unmet medical need in these patient populations, successful outcomes could position this combination as a competitive option in the oncology market. The results may also provide insights into the broader application of epigenetic therapies in hematologic cancers, potentially attracting interest from pharmaceutical companies looking to expand their oncology portfolios.
AI analysis
Indication: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Modality: small molecule
Target: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Sep 30, 2013
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Untreated Adult Acute Myeloid Leukemia
Condition normalized: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Untreated Adult Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.
Target normalized: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.
NCT04743115Source recordAI-normalized
A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
BS HH 002.SA is being developed by Shanghai Bensen Pharmaceutical Co., Ltd. for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS). The target patient population is significant due to the limited treatment options available for these conditions, suggesting a potentially lucrative market. The study's design includes a dose escalation and cohort expansion, indicating a strategic approach to establishing safety and efficacy. The competitive landscape includes other emerging therapies for AML and MDS, necessitating diligent monitoring of similar clinical trials and market entrants. The trial's current status is 'Not Yet Recruiting,' which may impact timelines for market entry and revenue generation.
AI analysis
Indication: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Modality: small molecule
Target: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.
Sponsor: Shanghai Bensen Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Feb 08, 2021
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Condition normalized: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.
Target normalized: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.
NCT03173248Source recordAI-normalized
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
AG-120 (ivosidenib) is being evaluated in combination with azacitidine for the treatment of previously untreated acute myeloid leukemia (AML) with an IDH1 mutation. This combination therapy targets a specific patient population that is not suitable for intensive chemotherapy, potentially expanding the market for IDH1 inhibitors in AML treatment. The global AML market is projected to grow significantly, driven by advancements in targeted therapies. Competitive landscape includes other IDH inhibitors and hypomethylating agents, necessitating careful monitoring of clinical outcomes and market positioning. Diligence should focus on the trial's efficacy and safety data, as well as regulatory pathways for approval.
AI analysis
Indication: Newly Diagnosed Acute Myeloid Leukemia (AML)
Modality: small molecule
Target: Isocitrate dehydrogenase 1 (IDH1) mutation
Sponsor: Institut de Recherches Internationales Servier
Source URL: ClinicalTrials.gov
Source updated: Nov 10, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Condition normalized: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Isocitrate dehydrogenase 1 (IDH1) mutation
Target normalized: Isocitrate dehydrogenase 1 (IDH1) mutation
NCT00504764Source recordAI-normalized
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
The APL-R2007 trial, sponsored by the PETHEMA Foundation, investigates the efficacy of arsenic trioxide (ATO) in treating relapsed acute promyelocytic leukemia (APL). ATO has demonstrated remission rates exceeding 80% in prior studies and is already approved for relapsed and refractory APL in both Europe and the USA. The market for APL therapies is competitive, with ATRA and other agents also in use. The trial's findings could reinforce ATO's position in the treatment landscape, particularly for patients not eligible for transplantation. Given the high relapse rates associated with APL, successful outcomes could lead to increased adoption of ATO in clinical practice, impacting market share and revenue potential for the PETHEMA Foundation and potential partners. Diligence should focus on the long-term safety profile and comparative efficacy against existing therapies.
AI analysis
Indication: Acute Promyelocytic Leukemia
Modality: small molecule
Target: PML/RARa fusion protein in acute promyelocytic leukemia (APL) cells, with a focus on apoptosis induction and differentiation of APL blasts.
Sponsor: PETHEMA Foundation
Source URL: ClinicalTrials.gov
Source updated: Oct 28, 2014
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Promyelocytic Leukemia
Condition normalized: Acute Promyelocytic Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PML/RARa fusion protein in acute promyelocytic leukemia (APL) cells, with a focus on apoptosis induction and differentiation of APL blasts.
Target normalized: PML/RARa fusion protein in acute promyelocytic leukemia (APL) cells, with a focus on apoptosis induction and differentiation of APL blasts.
NCT04588649Source recordAI-normalized
The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke
The study, sponsored by Chang Gung Memorial Hospital, investigates the interplay between vascular injury, amyloid plaques, and tau proteins in cognitive dysfunction following stroke. With approximately one-third of stroke patients developing post-stroke dementia, this research addresses a significant unmet medical need in the aging population. The findings could inform the development of diagnostic tools or therapeutic strategies targeting cognitive impairment in stroke patients, potentially positioning the sponsor as a leader in this niche market. The competitive landscape includes other neuroimaging studies and dementia-related therapeutics, necessitating a thorough diligence assessment to identify potential collaborators or competitors in the field.
AI analysis
Indication: Post-stroke Dementia
Modality: small molecule
Target: Vascular injury, amyloid plaque, and tau protein as contributors to cognitive dysfunction post-stroke.
Sponsor: Chang Gung Memorial Hospital
Source URL: ClinicalTrials.gov
Source updated: May 06, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Post-stroke Dementia, Vascular Mild Cognitive Impairment
Condition normalized: Post-stroke Dementia, Vascular Mild Cognitive Impairment
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Vascular injury, amyloid plaque, and tau protein as contributors to cognitive dysfunction post-stroke.
Target normalized: Vascular injury, amyloid plaque, and tau protein as contributors to cognitive dysfunction post-stroke.
NCT00954252Source recordAI-normalized
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects
CHF 5074, developed by CERESPIR, is positioned as a novel gamma-secretase modulator aimed at treating Alzheimer's disease by reducing amyloid-beta levels. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. The competitive landscape includes several established players and emerging biotech firms focused on similar mechanisms. Given the high unmet need in Alzheimer's treatment, successful outcomes in this trial could enhance CERESPIR's market position and attract potential partnerships or acquisition interest. Diligence should focus on the safety profile and pharmacokinetic data to assess viability for further development.
AI analysis
Indication: Alzheimer's Disease
Modality: small molecule
Target: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.
Sponsor: CERESPIR
Source URL: ClinicalTrials.gov
Source updated: Feb 10, 2015
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.
Target normalized: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.
NCT07105709Source recordAI-normalized
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease
GSK4527226 is positioned within a competitive landscape of Alzheimer's Disease therapies, particularly targeting early-stage patients with mild cognitive impairment and mild dementia. The market for Alzheimer's treatments is substantial, with increasing demand for effective disease-modifying therapies. GSK's collaboration with Alector Inc. may enhance its development capabilities and market reach. The success of this trial could provide GSK with a significant foothold in the Alzheimer's market, which is currently underserved, particularly for early intervention strategies.
AI analysis
Indication: Alzheimer's Disease
Modality: small molecule
Target: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Feb 02, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.
Target normalized: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.
NCT04744532Source recordAI-normalized
Phase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
The Phase 1/2 study of bosutinib in ALS patients, sponsored by Kyoto University, represents a potential breakthrough in the treatment of amyotrophic lateral sclerosis (ALS), particularly for patients with SOD1 mutations. The market for ALS therapies is growing, with limited options currently available, primarily edaravone and riluzole. The successful development of bosutinib could position it as a competitive alternative, especially if it demonstrates significant efficacy and safety in the trial. The collaboration with multiple universities and Pfizer enhances credibility and may facilitate broader clinical acceptance and potential commercialization. However, the competitive landscape remains challenging, with ongoing research into novel therapies for ALS, necessitating diligent monitoring of trial outcomes and competitor developments.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
Sponsor: Kyoto University
Source URL: ClinicalTrials.gov
Source updated: Mar 08, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
Target normalized: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
NCT04307576Source recordAI-normalized
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
The ALLTogether1 clinical trial represents a significant advancement in the treatment of Acute Lymphoblastic Leukaemia (ALL) in children and young adults, with an estimated enrollment of 6,430 participants across multiple European countries. The trial's comprehensive master protocol aims to improve survival rates and reduce treatment-related toxicities through innovative risk stratification and targeted therapies. The involvement of major pharmaceutical companies such as Pfizer, Amgen, and Servier indicates strong industry interest and potential for collaboration. Given the high incidence of ALL and the ongoing need for improved treatment options, successful outcomes from this trial could lead to substantial market opportunities and competitive advantages for the involved sponsors and collaborators. The trial's design also allows for modular adaptations, which may facilitate rapid incorporation of new therapeutic agents as they become available.
AI analysis
Indication: Leukemia, Acute Lymphoblastic
Modality: small molecule
Target: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
Sponsor: Mats Heyman
Source URL: ClinicalTrials.gov
Source updated: May 05, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Leukemia, Acute Lymphoblastic
Condition normalized: Leukemia, Acute Lymphoblastic
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
Target normalized: Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.
NCT01536249Source recordAI-normalized
An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers
Knopp Biosciences' study on dexpramipexole, an investigational drug for ALS, aims to elucidate the pharmacokinetic interactions with cimetidine. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes could position dexpramipexole favorably in a niche market. The study's completion in 2012 suggests that data may be available for further development or partnership opportunities. However, the competitive landscape includes other emerging therapies for ALS, necessitating a thorough analysis of dexpramipexole's unique value proposition and potential market differentiation.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
Sponsor: Knopp Biosciences
Source URL: ClinicalTrials.gov
Source updated: Nov 25, 2014
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
Target normalized: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
NCT06964009Source recordAI-normalized
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
The clinical trial for DT2216, a BCL-XL degrader, in combination with paclitaxel, targets recurrent platinum-resistant ovarian cancer, a significant unmet medical need in oncology. The study aims to establish the maximum tolerated dose (MTD) and evaluate safety, which could position DT2216 as a novel therapeutic option in a competitive landscape dominated by established chemotherapies. Given the FDA's approval of paclitaxel, the combination therapy may enhance treatment efficacy and patient outcomes. The involvement of the Department of Defense and Dialectic Therapeutics indicates potential for strategic partnerships and funding opportunities. Market entry could disrupt existing treatment paradigms if safety and efficacy are demonstrated, leading to significant commercial potential in a market projected to grow as new therapies are sought for resistant cancer types.
AI analysis
Indication: Ovarian Cancer
Modality: small molecule
Target: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
Sponsor: Elizabeth Stover, MD, PhD
Source URL: ClinicalTrials.gov
Source updated: Apr 21, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Condition normalized: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
Target normalized: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
NCT07104110Source recordAI-normalized
An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
QLH12016, an investigational oral AR PROTAC, is being evaluated in combination with novel hormonal agents (NHA) such as abiraterone acetate and enzalutamide for the treatment of advanced prostate cancer. The prostate cancer therapeutics market is projected to grow significantly, driven by increasing incidence rates and advancements in treatment options. The combination therapy approach may provide a competitive edge against existing monotherapies and combinations, particularly in patients who have progressed on standard treatments. Qilu Pharmaceutical Co., Ltd. is positioning itself in a niche segment of the prostate cancer market, which could enhance its portfolio and market share if the trial demonstrates favorable safety and efficacy outcomes. Diligence should focus on the competitive landscape, particularly the performance of existing therapies and emerging candidates in similar indications.
AI analysis
Indication: Prostatic Neoplasms
Modality: small molecule
Target: Androgen Receptor (AR) via PROTAC mechanism
Sponsor: Qilu Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Aug 05, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Prostatic Neoplasms
Condition normalized: Prostatic Neoplasms
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Androgen Receptor (AR) via PROTAC mechanism
Target normalized: Androgen Receptor (AR) via PROTAC mechanism
NCT05654623Source recordAI-normalized
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
ARV-471 (PF-07850327) is being evaluated against fulvestrant in a pivotal Phase 3 trial for ER+/HER2- advanced breast cancer patients who have progressed after prior endocrine therapy. The market for advanced breast cancer treatments is significant, with a growing demand for novel therapies that can overcome resistance to existing treatments. If successful, ARV-471 could capture a substantial share of the market, particularly given the limitations of current therapies like fulvestrant. Competitive implications include positioning against other SERDs and emerging therapies targeting similar patient populations. Diligence should focus on the trial's primary and secondary endpoints, safety profile, and potential market entry timelines.
AI analysis
Indication: Advanced Breast Cancer
Modality: small molecule
Target: Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Mar 18, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Advanced Breast Cancer
Condition normalized: Advanced Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).
Target normalized: Estrogen Receptor (ER) degradation via PROTAC mechanism (specifically targeting ER+ breast cancer).
NCT05573555Source recordAI-normalized
TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)
The TACTIVE-U study, sponsored by Pfizer, is investigating the safety and efficacy of ARV-471, an oral proteolysis targeting chimera, in combination with ribociclib for the treatment of advanced or metastatic ER+ breast cancer. The study is particularly relevant given the increasing prevalence of breast cancer and the need for effective therapies in patients who have exhausted prior treatment options. The combination therapy could provide a competitive edge in the oncology market, especially as CDK4/6 inhibitors like ribociclib have established their role in breast cancer treatment. Pfizer's collaboration with Arvinas enhances its portfolio in targeted therapies, potentially positioning it favorably against competitors in the rapidly evolving oncology landscape.
AI analysis
Indication: Breast Cancer
Modality: small molecule
Target: Estrogen Receptor Positive (ER+) signaling pathway, specifically targeting estrogen receptor degradation via proteolysis targeting chimera (PROTAC) mechanism.
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Mar 09, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Estrogen Receptor Positive (ER+) signaling pathway, specifically targeting estrogen receptor degradation via proteolysis targeting chimera (PROTAC) mechanism.
Target normalized: Estrogen Receptor Positive (ER+) signaling pathway, specifically targeting estrogen receptor degradation via proteolysis targeting chimera (PROTAC) mechanism.
NCT04606446Source recordAI-normalized
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
PF-07248144, developed by Pfizer, is currently undergoing a Phase 1/2A clinical trial targeting advanced or metastatic solid tumors, specifically focusing on ER+HER2- breast cancer, castration-resistant prostate cancer (CRPC), and non-small cell lung cancer (NSCLC). The trial's design includes both monotherapy and combination therapy approaches, which may enhance its market potential by addressing treatment-resistant cancers. The competitive landscape includes established therapies such as CDK4/6 inhibitors and endocrine therapies, necessitating a strong efficacy and safety profile to differentiate PF-07248144. Given the increasing prevalence of these cancers and the demand for novel treatment options, successful outcomes could position PF-07248144 favorably within a lucrative oncology market. The estimated enrollment of 320 participants indicates a robust commitment to generating significant clinical data, which could attract interest from investors and stakeholders in the oncology space.
AI analysis
Indication: Locally Advanced or Metastatic ER+ HER2- Breast Cancer
Modality: small molecule
Target: KAT6 Inhibitor
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Apr 16, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Condition normalized: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: KAT6 Inhibitor
Target normalized: KAT6 Inhibitor
NCT03796884Source recordAI-normalized
Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer
Linaclotide, a small protein targeting the GUCY2C receptor, is being evaluated for its efficacy in patients with stages 0-3 colorectal cancer and sporadic colorectal adenomas. The trial is sponsored by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and is currently active but not recruiting. The market for colorectal cancer therapies is significant, with increasing demand for innovative treatments that can improve patient outcomes. If successful, linaclotide could enhance the therapeutic landscape for colorectal cancer, particularly in early-stage disease, potentially positioning it favorably against existing therapies. The collaboration with the U.S. Department of Defense may also provide additional funding and support for further development. Diligence should focus on the competitive landscape, particularly other agents targeting GUCY2C and their clinical progress.
AI analysis
Indication: Colorectal Adenoma
Modality: small molecule
Target: Guanylate cyclase C (GUCY2C) receptor
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Source URL: ClinicalTrials.gov
Source updated: Apr 02, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
Condition normalized: Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Guanylate cyclase C (GUCY2C) receptor
Target normalized: Guanylate cyclase C (GUCY2C) receptor
NCT03392298Source recordAI-normalized
Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia
The study investigates the efficacy of Colla corii asini (CCA) in treating anemia in pregnant women with beta-thalassemia, a significant health concern in regions with high thalassemia prevalence, such as Southern China. The potential market for CCA as a therapeutic agent could be substantial, given the lack of safe and effective treatments for this demographic. The findings may position CCA as a viable alternative to conventional therapies, which often have severe side effects. Competitive analysis indicates a niche market with limited direct competition in the use of traditional Chinese medicine for this indication, presenting an opportunity for differentiation and market entry. Diligence implications include the need for thorough evaluation of safety and efficacy data, as well as potential regulatory pathways for traditional medicine integration into standard care.
AI analysis
Indication: Thalassemia
Modality: small molecule
Target: Regulation of globin gene expression pathways in beta-thalassemia patients, specifically targeting alpha, beta, gamma, and delta globin levels.
Sponsor: The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Source URL: ClinicalTrials.gov
Source updated: Jan 16, 2018
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Thalassemia, Pregnancy
Condition normalized: Thalassemia, Pregnancy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Regulation of globin gene expression pathways in beta-thalassemia patients, specifically targeting alpha, beta, gamma, and delta globin levels.
Target normalized: Regulation of globin gene expression pathways in beta-thalassemia patients, specifically targeting alpha, beta, gamma, and delta globin levels.
NCT00130247Source recordAI-normalized
A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment
This clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), investigates the efficacy of a shortened 4-month anti-TB treatment regimen compared to the standard 6-month regimen in HIV-non-infected patients with drug-susceptible pulmonary tuberculosis. The trial's completion and results could significantly impact treatment guidelines, potentially leading to increased patient adherence and reduced healthcare costs. The market for tuberculosis treatment remains substantial, especially in endemic regions, and successful outcomes may enhance the competitive positioning of existing therapies. Companies involved in TB treatment may need to evaluate their portfolios in light of these findings, particularly regarding the potential for shorter treatment regimens to gain market share.
AI analysis
Indication: Tuberculosis
Modality: small molecule
Target: Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Source URL: ClinicalTrials.gov
Source updated: Nov 08, 2018
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Tuberculosis
Condition normalized: Tuberculosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.
Target normalized: Mycobacterium tuberculosis (MTB) - targeting bacterial replication and survival mechanisms through standard anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol.
NCT00656825Source recordAI-normalized
Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers.
The P144 peptide inhibitor, developed by ISDIN, targets TGF-β1, a key mediator in fibrotic diseases, particularly systemic sclerosis. Given the lack of approved treatments for skin fibrosis associated with systemic sclerosis in both the EU and the US, P144 presents a significant market opportunity. The trial's focus on topical administration suggests a potential for a novel therapeutic approach in dermatology. The competitive landscape includes existing antifibrotic therapies, but P144's mechanism of action may provide a differentiated profile. Diligence should focus on the safety and tolerability data from the trial, as well as the regulatory pathway for approval.
AI analysis
Indication: Healthy
Modality: small molecule
Target: Transforming Growth Factor-beta 1 (TGF-β1) type III receptor (betaglycan)
Sponsor: ISDIN
Source URL: ClinicalTrials.gov
Source updated: Nov 05, 2008
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Healthy
Condition normalized: Healthy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Transforming Growth Factor-beta 1 (TGF-β1) type III receptor (betaglycan)
Target normalized: Transforming Growth Factor-beta 1 (TGF-β1) type III receptor (betaglycan)
NCT02357836Source recordAI-normalized
Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer
The Phase 0 study of itraconazole in early-stage non-small cell lung cancer (NSCLC) aims to explore its pharmacodynamic effects on tumor angiogenesis and the Hedgehog pathway. Given the high prevalence of NSCLC and the limited treatment options available for early-stage patients, this study could position itraconazole as a novel therapeutic option, particularly in combination with surgical resection. The findings may enhance the competitive landscape for NSCLC treatments, especially against existing anti-angiogenic therapies. Investors and stakeholders should consider the implications of these results on market positioning and potential partnerships for further development.
AI analysis
Indication: Non-small Cell Lung Cancer
Modality: small molecule
Target: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
Sponsor: University of Texas Southwestern Medical Center
Source URL: ClinicalTrials.gov
Source updated: May 03, 2021
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
Target normalized: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
NCT04535505Source recordAI-normalized
Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes
The proposed CPA platform utilizing CRISPR technology aims to provide a rapid and accurate diagnostic tool for detecting Bordetella species and their associated drug resistance genes. Given the ongoing global concerns regarding pertussis outbreaks, this technology could address a significant unmet need in infectious disease diagnostics. However, the trial has been withdrawn, indicating potential challenges in development or execution. The competitive landscape includes existing diagnostic methods such as culture and PCR, which may limit market entry unless the new platform demonstrates superior accuracy and speed. Diligence is required to assess the reasons for withdrawal and any implications for future development or partnerships.
AI analysis
Indication: Pertussis
Modality: small molecule
Target: Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.
Sponsor: Children's Hospital of Fudan University
Source URL: ClinicalTrials.gov
Source updated: Sep 14, 2022
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Pertussis
Condition normalized: Pertussis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.
Target normalized: Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.
NCT04819841Source recordAI-normalized
A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease
Kamau Therapeutics is advancing nula-cel, a gene therapy product aimed at treating severe Sickle Cell Disease (SCD) through the correction of the HbS mutation. The market for SCD therapies is expanding, with increasing demand for innovative treatments that address the underlying genetic causes of the disease. As a first-in-human study, the results could position Kamau Therapeutics favorably against competitors in the gene therapy space, particularly those focusing on hematological disorders. The estimated completion dates suggest a timeline that could allow for early market entry if successful, potentially leading to significant revenue opportunities given the high unmet need in this patient population. However, the presence of established players in the gene therapy market necessitates careful monitoring of competitive developments and regulatory pathways.
AI analysis
Indication: Sickle Cell Disease
Modality: small molecule
Target: CRISPR-Cas9 edited and sickle mutation-corrected hematopoietic stem cells (HSPCs)
Sponsor: Kamau Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Mar 11, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Sickle Cell Disease
Condition normalized: Sickle Cell Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CRISPR-Cas9 edited and sickle mutation-corrected hematopoietic stem cells (HSPCs)
Target normalized: CRISPR-Cas9 edited and sickle mutation-corrected hematopoietic stem cells (HSPCs)
NCT04546893Source recordAI-normalized
Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia
Hebei Senlang Biotechnology Inc., Ltd. is developing SL1904B, an anti-CD19 CAR-T cell therapy targeting relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The market for CAR-T therapies is expanding, particularly in hematological malignancies, with increasing demand for effective treatments for relapsed or refractory cases. The competitive landscape includes established players like Novartis and Gilead, which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on regulatory pathways, potential partnerships, and reimbursement scenarios in the Chinese market, where the trial is currently recruiting patients.
AI analysis
Indication: B-ALL
Modality: small molecule
Target: CD19 (anti-CD19 CAR-T cells)
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Sep 14, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: B-ALL
Condition normalized: B-ALL
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CD19 (anti-CD19 CAR-T cells)
Target normalized: CD19 (anti-CD19 CAR-T cells)
NCT06994338Source recordAI-normalized
Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity
Tirzepatide, a GLP-1 receptor agonist, is currently being evaluated for its efficacy in reducing alcohol consumption and improving cardiometabolic health in adults with Alcohol Use Disorder (AUD) and obesity. The trial is sponsored by the University of Southern California and is actively recruiting participants. If successful, this indication could expand Tirzepatide's market potential beyond diabetes and obesity, tapping into the significant unmet need for effective treatments for AUD. The competitive landscape includes existing pharmacotherapies for AUD, such as naltrexone and acamprosate, but Tirzepatide's novel mechanism may offer a differentiated profile. Diligence should focus on the trial's design, recruitment pace, and any emerging safety or efficacy signals that could impact market entry timelines and commercial viability.
AI analysis
Indication: Alcohol Use Disorder
Modality: small molecule
Target: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
Sponsor: University of Southern California
Source URL: ClinicalTrials.gov
Source updated: Oct 14, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Alcohol Use Disorder, Obesity and Overweight, Alcohol
Condition normalized: Alcohol Use Disorder, Obesity and Overweight, Alcohol
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
Target normalized: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
NCT02294084Source recordAI-normalized
The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men
Sitagliptin, marketed as Januvia, is an established anti-diabetic medication with a significant market presence. This study explores its potential to activate brown adipose tissue, thereby enhancing energy expenditure and reducing obesity-related metabolic disorders. If successful, this could expand Sitagliptin's therapeutic indications beyond glycemic control to include obesity management, tapping into the growing market for obesity treatments. The competitive landscape includes other GLP-1 receptor agonists and emerging therapies targeting BAT activation. Diligence is warranted regarding the regulatory pathways for these new indications and the potential for additional patent protections based on novel mechanisms of action.
AI analysis
Indication: Neoplasms, Adipose Tissue
Modality: small molecule
Target: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
Sponsor: Ingrid Jazet
Source URL: ClinicalTrials.gov
Source updated: Jul 16, 2018
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Neoplasms, Adipose Tissue
Condition normalized: Neoplasms, Adipose Tissue
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
Target normalized: Glucagon-like peptide-1 (GLP-1) receptor agonism leading to brown adipose tissue (BAT) activation.
NCT05256810Source recordAI-normalized
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout
The purpose of this study is to: * Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants * Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in adult patients with gout * Part C: Evaluate the safety, tolerability and efficacy of ALN-XDH as add-on therapy in adult patients with gout
AI analysis
Indication: Gout
Modality: small molecule
Target: ALN-XDH, Placebo
Sponsor: Alnylam Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Mar 29, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Gout
Condition normalized: Gout
Modality raw: small molecule
Modality normalized: small molecule
Target raw: ALN-XDH, Placebo
Target normalized: ALN-XDH, Placebo
NCT04877756Source recordAI-normalized
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Phase 2a, prospective, randomized, double-blind, intra-subject, placebo-controlled, proof of concept study. Approximately twenty subjects will be randomized 1:1 to one of two treatment arms: Arm A: 2.0 mg/cm OLX10010 biweekly (every two weeks) Arm B: 5.0 mg/cm OLX10010 biweekly (every two weeks) Each treatment arm will have approximately 10 subjects. Each subject will receive both active (OLX10010) and control (placebo) treatment post-hypertrophic scar surgery biweekly (every two weeks) for a total of six doses. Dosing will occur post-surgery on Weeks 2, 4, 6, 8, 10, and 12. Post-treatment follow-up visits will occur at Weeks 18 and 24, and a long-term follow-up visit will occur at Month 12. The Patient and Observer Scar Assessment Scale (both physician and patient scales), Stony Brook Scar Evaluation Scale, Vancouver Scar Scale, and a photograph-based visual analog scale by blinded experts will be completed prior to scar revision surgery, at Weeks 2, 8, 12, 18, and 24, and at Month 12. The overall opinion responses on the physician scales of the POSAS at Week 24 will be used for primary endpoint analysis. The total length of the linear hypertrophic scar line will be divided equally for treatment with OLX10010 and placebo, injected intradermally per centimeter (cm). The OLX10010 end and placebo end of the scar line will be separated by a 2 cm or greater distance depending on the scar length. After the Week 24 visit, all data collected will be cleaned and all data management activities will be completed. After the database is frozen/locked, the primary endpoint efficacy analysis will be completed. If at least one of the treatment arms are shown to be appropriate to reduce recurrence of hypertrophic scars, all analyses will be performed. If the efficacy analysis of Arms A and B indicate the study doses are not as effective as expected, the sponsor may decide to add a third arm (Arm C) to explore the weekly dosing regimen. See detailed summary. Subjects in all study arms will continue in the study until their Month 12 visit. After all subjects complete that visit, data are collected, and data management activities are completed, Month 12 data will be analyzed.
AI analysis
Indication: Hypertrophic Scar
Modality: small molecule
Target: OLX10010
Sponsor: Olix Pharmaceuticals, Inc.
Source URL: ClinicalTrials.gov
Source updated: Feb 21, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Hypertrophic Scar
Condition normalized: Hypertrophic Scar
Modality raw: small molecule
Modality normalized: small molecule
Target raw: OLX10010
Target normalized: OLX10010
NCT00802347Source recordAI-normalized
Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation
The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donors or SCD donors with ≥ 24 hours of cold ischemia time who meet study entry criteria will be studied to evaluate the safety and pharmacokinetic profile of I5NP (Part A) and clinical activity of I5NP administration (Part B). Data from this study will be used to identify doses of I5NP to be used in follow-on efficacy studies. Part A will be a randomized, dose escalation study to determine the highest or maximum tolerated dose (MTD). Part A will enroll 40 patients at approximately 20 sites; patients will be randomized to receive either I5NP or placebo in a ratio of 8:2 in each cohort (cohorts 1-4). Part B will utilize the dose identified in Part A to further evaluate, in a double-blind manner, the safety, and clinical activity of I5NP. In Part B, up to 326 patients will participate at approximately 60 sites; up to 163 patients will be randomized to receive I5NP and up to 163 patients randomized to receive placebo.
AI analysis
Indication: Delayed Graft Function
Modality: small molecule
Target: I5NP, Saline
Sponsor: Quark Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Sep 18, 2014
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Delayed Graft Function, Other Complication of Kidney Transplant
Condition normalized: Delayed Graft Function, Other Complication of Kidney Transplant
Modality raw: small molecule
Modality normalized: small molecule
Target raw: I5NP, Saline
Target normalized: I5NP, Saline
NCT03681184Source recordAI-normalized
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
AI analysis
Indication: Primary Hyperoxaluria Type 1 (PH1)
Modality: small molecule
Target: Placebo, Lumasiran
Sponsor: Alnylam Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Aug 12, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Primary Hyperoxaluria Type 1 (PH1)
Condition normalized: Primary Hyperoxaluria Type 1 (PH1)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Placebo, Lumasiran
Target normalized: Placebo, Lumasiran
NCT05783206Source recordAI-normalized
Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Adult Outpatients With Mild COVID-19.
The aim of this study is to evaluate the effectiveness and safety of MIR 19 ® in preventing development of moderate and/or severe course of the disease in mild COVID-19 outpatients. Primary endpoint: The proportion of patients with the development of moderate or severe COVID-19 disease (in accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian Federation, version 14 of 27.12.2021 or current at the time of the study) by the 28th day of observation.
AI analysis
Indication: COVID-19
Modality: small molecule
Target: MIR 19 ®, Standard therapy
Sponsor: National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Source URL: ClinicalTrials.gov
Source updated: Dec 27, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: COVID-19
Condition normalized: COVID-19
Modality raw: small molecule
Modality normalized: small molecule
Target raw: MIR 19 ®, Standard therapy
Target normalized: MIR 19 ®, Standard therapy
NCT05929807Source recordAI-normalized
A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia
TransCon CNP administered once-weekly in children and adolescents with achondroplasia who have completed a prior TransCon CNP clinical trial. Participants who complete a prior TransCon CNP trial and meet all eligibility criteria will be invited to continue into the long-term open label extension trial to receive 100 µg CNP/kg/week of TransCon CNP. Trial treatment will be completed when the participant reaches 16 years of age for females and 18 years of age for males and have femur and tibial epiphyseal closure. TransCon CNP treatment will continue if femur and tibial epiphyseal closure is not confirmed at the age of 16 years for females, and 18 years for males. Treatment with TransCon CNP will be completed once femur and tibial epiphyseal closure is confirmed by radiographic imaging. The trial duration is individual for each trial participant. Visits will occur every 12-14 weeks throughout the trial.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: TransCon CNP
Sponsor: Ascendis Pharma Growth Disorders A/S
Source URL: ClinicalTrials.gov
Source updated: Oct 27, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: TransCon CNP
Target normalized: TransCon CNP
NCT03583697Source recordAI-normalized
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: BMN 111, Placebo
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Jun 13, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BMN 111, Placebo
Target normalized: BMN 111, Placebo
NCT05145010Source recordAI-normalized
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201 and subjects are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: Infigratinib, Infigratinib
Sponsor: QED Therapeutics, a BridgeBio company
Source URL: ClinicalTrials.gov
Source updated: Oct 31, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Infigratinib, Infigratinib
Target normalized: Infigratinib, Infigratinib
NCT06732895Source recordAI-normalized
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-18 Years of Age) With Achondroplasia.
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: Navepegritide, Placebo for navepegritide
Sponsor: Ascendis Pharma A/S
Source URL: ClinicalTrials.gov
Source updated: Apr 21, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Navepegritide, Placebo for navepegritide
Target normalized: Navepegritide, Placebo for navepegritide
NCT01435629Source recordAI-normalized
Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]
This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).
AI analysis
Indication: Genetic Disorder
Modality: small molecule
Target: somatropin
Sponsor: Novo Nordisk A/S
Source URL: ClinicalTrials.gov
Source updated: May 05, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Genetic Disorder, Achondroplasia
Condition normalized: Genetic Disorder, Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: somatropin
Target normalized: somatropin
NCT01590446Source recordAI-normalized
A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers
The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: BMN 111, Normal Saline
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Jun 11, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BMN 111, Normal Saline
Target normalized: BMN 111, Normal Saline
NCT03424018Source recordAI-normalized
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: BMN 111
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Mar 13, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BMN 111
Target normalized: BMN 111
NCT02055157Source recordAI-normalized
A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
AI analysis
Indication: Achondroplasia
Modality: small molecule
Target: BMN 111
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Jan 15, 2021
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BMN 111
Target normalized: BMN 111
NCT04387630Source recordAI-normalized
Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.
Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.
AI analysis
Indication: Breast Cancer
Modality: small molecule
Target: Metformin, Placebo oral tablet
Sponsor: Mansoura University
Source URL: ClinicalTrials.gov
Source updated: Jun 11, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Metformin, Placebo oral tablet
Target normalized: Metformin, Placebo oral tablet
NCT05576324Source recordAI-normalized
Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis
The aim of this study is to investigate the frequency distribution, cytokine profile and function of peripheral, mononuclear leukocyte populations (monocytes, NK cells, T/B lymphocytes) and their correlation to clinical and biochemical parameters in patients with cystic fibrosis receiving CFTR modulatory triple therapy consisting of elexacaftor, tezacaftor and ivacaftor and to compare it with patients without CFTR modulatory therapy and healthy control subjects.
AI analysis
Indication: Cystic Fibrosis
Modality: small molecule
Target: Elexacaftor / Ivacaftor / Tezacaftor
Sponsor: University of Erlangen-Nürnberg Medical School
Source URL: ClinicalTrials.gov
Source updated: Oct 12, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Cystic Fibrosis
Condition normalized: Cystic Fibrosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Elexacaftor / Ivacaftor / Tezacaftor
Target normalized: Elexacaftor / Ivacaftor / Tezacaftor
NCT01082731Source recordAI-normalized
A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil
Data on the burden of MIP in low transmission areas, such as Latin America, are very limited; there is even less information on the efficacy of case management of MiP. The treatment recommendations for MiP in Latin American countries have been changing rapidly in recent months; currently, either artemether-lumefantrine (AL) or mefloquine-artesunate (MA) is the first line treatment for P. falciparum (depending on country); however, no data exists on the efficacy of these drugs for the treatment of malaria in pregnancy in Latin America to support their use. We propose a multi-center 2-arm open-label randomized Phase 4 clinical trial to assess safety and efficacy of the present therapies, AL and MA. We hypothesize that the drugs will both be efficacious for use in pregnant women in Brazil.
AI analysis
Indication: Malaria
Modality: small molecule
Target: Artemether-Lumefantrine, Mefloquine- Artesunate
Sponsor: Centers for Disease Control and Prevention
Source URL: ClinicalTrials.gov
Source updated: Apr 13, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Malaria
Condition normalized: Malaria
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Artemether-Lumefantrine, Mefloquine- Artesunate
Target normalized: Artemether-Lumefantrine, Mefloquine- Artesunate
NCT03853044Source recordAI-normalized
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.
AI analysis
Indication: Angioimmunoblastic T-cell Lymphoma
Modality: small molecule
Target: Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Sponsor: Ruijin Hospital
Source URL: ClinicalTrials.gov
Source updated: Apr 20, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Angioimmunoblastic T-cell Lymphoma
Condition normalized: Angioimmunoblastic T-cell Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Target normalized: Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
NCT02980341Source recordAI-normalized
Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.
AI analysis
Indication: Metastatic Breast Cancer
Modality: small molecule
Target: Patritumab Deruxtecan
Sponsor: Daiichi Sankyo Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Oct 30, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Metastatic Breast Cancer
Condition normalized: Metastatic Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Patritumab Deruxtecan
Target normalized: Patritumab Deruxtecan
NCT00712582Source recordAI-normalized
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks. Each three weeks is a cycle. Some factors predict that you may not be cured with R-CHOP-21. The most common ones are: * Stage - how much DLBCL, PMBL, or FL3B you have * LDH - a blood chemistry marker; and * Whether you can do your normal daily activities. (performance status) We think that the best way to cure more patients with poor risk factors is to add new treatment to R-CHOP. You will get different chemotherapy after 4 cycles. This type of treatment is called risk-adapted therapy.
AI analysis
Indication: Non-Hodgkin's Lymphoma
Modality: small molecule
Target: Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Sponsor: Memorial Sloan Kettering Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Jun 21, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Non-Hodgkin's Lymphoma
Condition normalized: Non-Hodgkin's Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Target normalized: Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
NCT02918747Source recordAI-normalized
P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's lymphoma and shows extremely poor survival. Several retrospective studies and singe-arm prospective phase 2 studies have shown that pegaspargase combined Gemox or CHOP regimen achieved a promising efficacy in treatment of ENKTL. However, there is no prospective study to compare the efficacy of these two regimens. This prospective pilot study to compare the efficacy and safety of the P-Gemoxd chemotherapy regimen with those of the P-CHOP regimen for stage IE to IIE ENKTL.
AI analysis
Indication: Lymphoma
Modality: small molecule
Target: pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT
Sponsor: Hunan Cancer Hospital
Source URL: ClinicalTrials.gov
Source updated: Jan 28, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Lymphoma
Condition normalized: Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT
Target normalized: pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT
NCT01498588Source recordAI-normalized
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Previous studies have shown that chemotherapy has the same effect on treating breast cancer whether you receive it before or after surgery. Receiving chemotherapy before surgery, rather than after surgery, may allow the patient to have less extensive surgery. The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of eribulin followed by doxorubicin and cyclophosphamide can shrink the size of the patient's breast tumor and allow you to preserve your breast. Additionally, by receiving chemotherapy before surgery, the investigators will be able to determine if your cancer is responsive to chemotherapy.
AI analysis
Indication: Breast Neoplasms
Modality: small molecule
Target: Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
Sponsor: Emory University
Source URL: ClinicalTrials.gov
Source updated: Oct 03, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Condition normalized: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
Target normalized: Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim
NCT00447304Source recordAI-normalized
Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study
Acute cholecystitis is frequent in the elderly, or in patients with gall stones. Most cases of severe or recurrent cholecystitis need surgery as final therapy. Today, the performed procedure in most cases for cholecystectomy in the western world is laparoscopic cholecystectomy. Only in some cases an open surgery has to be performed. Unclear is, what time point is best, concerning outcome and morbidity of the patient, immediate surgery or initial conservative therapy using antibiotics and symptomatic therapy with cholecystectomy later on. Today the performed procedure is mainly chosen by the fact, what doctor sees the patient first, surgeon or gastroenterologist. This study is performed to evaluate if one therapy is superior.
AI analysis
Indication: Acute Cholecystitis
Modality: small molecule
Target: moxifloxacin, cholecystectomy
Sponsor: Heidelberg University
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Cholecystitis
Condition normalized: Acute Cholecystitis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: moxifloxacin, cholecystectomy
Target normalized: moxifloxacin, cholecystectomy
NCT02285062Source recordAI-normalized
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
AI analysis
Indication: Lymphoma, Large B-Cell, Diffuse
Modality: small molecule
Target: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Sponsor: Celgene
Source URL: ClinicalTrials.gov
Source updated: Jun 22, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Lymphoma, Large B-Cell, Diffuse
Condition normalized: Lymphoma, Large B-Cell, Diffuse
Modality raw: small molecule
Modality normalized: small molecule
Target raw: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Target normalized: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
NCT01501487Source recordAI-normalized
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients. This study is designed to test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (LABC).
AI analysis
Indication: Breast Cancer
Modality: small molecule
Target: TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Sponsor: Agendia
Source URL: ClinicalTrials.gov
Source updated: Jun 28, 2018
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Target normalized: TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
NCT04546620Source recordAI-normalized
A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib
This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy. All patients will receive one cycle of R-CHOP. Two thirds of patients (Arm B) will go on to receive a further 5 cycles (every 21 days) of R-CHOP with Acalabrutinib. Acalabrutinib will be taken orally twice daily continuously in 21 day cycles. One third of patients (Arm A) will continue with 5 cycles of R-CHOP. Patients will be followed up initially for 24 months and then for disease status and survival until 114 progression events have been observed.
AI analysis
Indication: Diffuse Large B Cell Lymphoma
Modality: small molecule
Target: R-CHOP, R-CHOP + acalabrutinib
Sponsor: University Hospital Southampton NHS Foundation Trust
Source URL: ClinicalTrials.gov
Source updated: Apr 30, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Diffuse Large B Cell Lymphoma
Condition normalized: Diffuse Large B Cell Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: R-CHOP, R-CHOP + acalabrutinib
Target normalized: R-CHOP, R-CHOP + acalabrutinib
NCT04079140Source recordAI-normalized
Benefits of Self-administered Vaginal Dinoprostone Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women: a Randomized Controlled Trial
To investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing intrauterine system(IUs) insertion reduces IUD insertion pain and difficulty in insertion in adolescents and young women.
AI analysis
Indication: IUD Insertion Pain
Modality: small molecule
Target: Dinoprostone, placebo
Sponsor: Cairo University
Source URL: ClinicalTrials.gov
Source updated: Jul 31, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: IUD Insertion Pain
Condition normalized: IUD Insertion Pain
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dinoprostone, placebo
Target normalized: Dinoprostone, placebo
NCT07020117Source recordAI-normalized
NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
AI analysis
Indication: Urothelial Carcinoma Bladder
Modality: small molecule
Target: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Sponsor: Aktis Oncology, Inc.
Source URL: ClinicalTrials.gov
Source updated: Apr 21, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Condition normalized: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Target normalized: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
NCT01280526Source recordAI-normalized
A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas
This study is an open label, multicenter study with two phases: * A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma. * An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.
AI analysis
Indication: Peripheral T Cell Lymphoma
Modality: small molecule
Target: Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP
Sponsor: The Lymphoma Academic Research Organisation
Source URL: ClinicalTrials.gov
Source updated: May 22, 2014
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Peripheral T Cell Lymphoma
Condition normalized: Peripheral T Cell Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP
Target normalized: Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP
NCT04495088Source recordAI-normalized
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure
AI analysis
Indication: Rectal Cancer
Modality: small molecule
Target: mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)
Sponsor: Ralf Hofheinz
Source URL: ClinicalTrials.gov
Source updated: Feb 02, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Rectal Cancer
Condition normalized: Rectal Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)
Target normalized: mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)
NCT00635258Source recordAI-normalized
Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.
This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.
AI analysis
Indication: Pregnancy
Modality: small molecule
Target: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)
Sponsor: Centro Ginecologia y Obstetricia.
Source URL: ClinicalTrials.gov
Source updated: Mar 13, 2008
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Pregnancy, Embryo Implantation
Condition normalized: Pregnancy, Embryo Implantation
Modality raw: small molecule
Modality normalized: small molecule
Target raw: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)
Target normalized: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain), GnRH antagonist (Orgalutran®)
NCT00184002Source recordAI-normalized
A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
The current standard treatment for non-Hodgkin's lymphoma involves drugs called cyclophosphamide, doxorubicin, vincristine, prednisone and rituxan in a regimen called "R-CHOP." Using R-CHOP therapy, complete disappearance of disease is expected in over 50% of people. One of the active drugs in the R-CHOP regimen, doxorubicin, has previously been reformulated and been placed in a fatty bubble called a liposome. The reason for placing the drug in the liposome is that there is evidence that the liposome is better taken up by tumors. This liposomally encapsulated form of doxorubicin called Doxil has shown similar or better anti-tumor against certain tumors with reduced side effects. Doxil is FDA approved for ovarian cancer. However its use in non-Hodgkin's lymphoma is still investigational. By substituting Doxil for doxorubicin in the R-CHOP regimen, it is hoped this treatment will be better at shrinking tumors and with reduced side effects. The purpose of this study is to see how well the combination of Doxil, rituximab, cyclophosphamide, vincristine and prednisone (DR-COP) are in shrinking tumors in patients with non-Hodgkin's lymphoma.
AI analysis
Indication: Non-Hodgkin's Lymphoma
Modality: small molecule
Target: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Sponsor: University of Southern California
Source URL: ClinicalTrials.gov
Source updated: Aug 10, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Non-Hodgkin's Lymphoma
Condition normalized: Non-Hodgkin's Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Target normalized: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
NCT05032937Source recordAI-normalized
Clinical Study of Domestic Polysaccharide Superparamagnetic Iron Oxide Nanoparticle Injection for Coronary Artery Contrast-enhanced Magnetic Resonance Contrast-enhanced Angiography
This is a single-center, prospective, controlled and diagnostic clinical trial which will enroll 30 patients scheduled for coronary angiography in China.Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.In order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination.The main indicators of the study are the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.
AI analysis
Indication: Coronary Heart Disease
Modality: small molecule
Target: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Source URL: ClinicalTrials.gov
Source updated: Jan 13, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Coronary Heart Disease
Condition normalized: Coronary Heart Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Target normalized: domestic polysaccharide superparamagnetic iron oxide nanoparticle
NCT02707809Source recordAI-normalized
Effects of Perioperative Dexmedetomidine Infusion on Microcirculation and Kidney and Intestinal Injury in Kidney Transplant Recipients
The microcirculation is altered in acute kidney injury and chronic kidney disease. The microcirculation is poor in end-stage renal disease patients receiving hemodialysis. Kidney transplant can improve the life quality of these patients. However, surgical stress and inflammatory response may cause microcirculatory dysfunction and intestinal injury. Moreover, the transplanted kidney would suffer from the ischemia and reperfusion injury, and it may result in acute kidney injury. In ischemia and reperfusion injury animal model, dexmedetomidine has been proven to attenuate kidney and intestinal injury. In our previous study of surgical stress and pain stimulation rat model, we found that dexmedetomidine attenuate the intestinal microcirculatory dysfunction. In patients receiving coronary artery bypass graft surgery, dexmedetomidine increases urine output and decreases postoperative serum level of neutrophil gelatinase-associated lipocalin. This study aims to investigate whether perioperative dexmedetomidine infusion may attenuate microcirculatory dysfunction, kidney injury, and intestinal injury for patients undergoing kidney transplant.
AI analysis
Indication: Kidney Disease
Modality: small molecule
Target: Dexmedetomidine
Sponsor: National Taiwan University Hospital
Source URL: ClinicalTrials.gov
Source updated: Dec 17, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Kidney Disease
Condition normalized: Kidney Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dexmedetomidine
Target normalized: Dexmedetomidine
NCT01137786Source recordAI-normalized
A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.
AI analysis
Indication: Coronary Artery Stenosis
Modality: small molecule
Target: Non ionic contrast media comparator, Non ionic contrast media comparator
Sponsor: Bracco Diagnostics, Inc
Source URL: ClinicalTrials.gov
Source updated: Sep 30, 2013
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Coronary Artery Stenosis
Condition normalized: Coronary Artery Stenosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Non ionic contrast media comparator, Non ionic contrast media comparator
Target normalized: Non ionic contrast media comparator, Non ionic contrast media comparator
NCT00878956Source recordAI-normalized
A Phase IIb Multiple Blind Randomized Controlled Trial of Sodium Bicarbonate in Cardiac Surgery at High-risk of Acute Kidney Injury
With over one million operations a year, cardiac surgery with cardiopulmonary bypass is one of the most common major surgical procedures worldwide (1). Acute kidney injury is a common and serious postoperative complication of cardiopulmonary bypass and may affect 25% to 50% of patients (2-4). Acute kidney injury carries significant costs (4) and is independently associated with increased morbidity and mortality (2,3). Even minimal increments in plasma creatinine are associated with an increase in mortality (5,6). Multiple causes of cardiopulmonary bypass-associated acute kidney injury have been proposed, including ischemia-reperfusion, generation of reactive oxygen species, hemolysis and activation of inflammatory pathways (7-10). To date, no simple, safe and effective intervention to prevent cardiopulmonary bypass-associated acute kidney injury in a broad patient population has been found (11-14). Urinary acidity may enhance the generation and toxicity of reactive oxygen species induced by cardiopulmonary bypass (10,15). Activation of complement during cardiac surgery (16) may also participate in kidney injury. Urinary alkalinization may protect from kidney injury induced by oxidant substances, iron-mediated free radical pathways, complement activation and tubular hemoglobin cast formation (9,17,18). Of note, increasing urinary pH - in combination with N-acetylcysteine (19,20) or without (21) - has recently been reported to attenuate acute kidney injury in patients undergoing contrast-media infusion. In a pilot double-blind, randomized controlled trial the investigators found sodium bicarbonate to be efficacious, safe, inexpensive and easy to administer. These findings now need to be confirmed or refuted by further clinical investigations in other geographic and institutional settings. Accordingly, the investigators hypothesized that urinary alkalinization might protect kidney function in patients at increased risk of acute kidney injury undergoing cardiopulmonary bypass needs to be confirmed in an international multicenter, double-blind, randomized controlled trial of intravenous sodium bicarbonate.
AI analysis
Indication: Acute Kidney Injury
Modality: small molecule
Target: Sodium Bicarbonate, Sodium Chloride
Sponsor: Austin Health
Source URL: ClinicalTrials.gov
Source updated: Aug 01, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Kidney Injury
Condition normalized: Acute Kidney Injury
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Sodium Bicarbonate, Sodium Chloride
Target normalized: Sodium Bicarbonate, Sodium Chloride
NCT01731457Source recordAI-normalized
Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function
The aims of this study are: 1. assessment of ischemia injury of kidney retrieved from standard and expanded criteria deceased donor before transplantation 2. assessment of efficacy of kidney ischemia injury decreasing 3. assessment of influence of kidney ischemia injury decreasing on its function after transplantation For the purpose of this research one hundred kidney will be retrieved from deceased donors (standard and expanded criteria deceased donors) for transplantation. All kidneys before transplantation will be stored in machine perfusion in hypothermia with continuous flow - Organ Recovery Systems LifePort - each single kidney in self-contained perfusion system. For the kidney allograft assessment will be used measurements performed during machine perfusion in hypothermia: renal flow, resistance, lactate dehydrogenase, lactates and ischemia injury markers measured in the fourth hour of perfusion in perfusion fluid. For kidney ischemia injury assessment such markers will be measured: tumour necrosis factor (TNF alfa), interleukin 2 (IL-2), interleukin 6 (IL-6), high sensitivity C-reactive protein (hsCRP), platelet-derived growth factor (PDGF), cystatin C, kidney Injury Molecule (KIM-1), neutrophil Gelatinase-associated Lipocalin (NGAL), complement component C3, caspase 3. Every time from pair of retrieved kidneys each kidney will be randomise for one of the group: * group 1) - 50 kidneys - examined group - "cured" with etanercept (ENBREL) in the first hour of perfusion by adding drug to perfusion fluid, * group 2) - 50 kidneys - control group - without intervention. Ischemia injury markers will be measured in perfusion fluid by kidney two times (in the first and fourth hour of perfusion) for assessment of efficacy kidney ischemia injury decreasing. Results of measurements of kidney ischemia injury before transplantation, parameters during machine perfusion in hypothermia and donor parameters will be correlated with kidney allograft function post transplantation. Immediate, delayed and slow graft function, primary non-function, kidney function assessed by creatinine concentration and creatinine clearance at one day, seven days, two weeks, 1, 6 and 12 months post transplantation and kidney graft survival 6 and 12 months post transplantation will be analysed.
AI analysis
Indication: Transplanted Kidney Ischemia Reperfusion Injury
Modality: small molecule
Target: etanercept
Sponsor: Medical University of Warsaw
Source URL: ClinicalTrials.gov
Source updated: May 10, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Transplanted Kidney Ischemia Reperfusion Injury
Condition normalized: Transplanted Kidney Ischemia Reperfusion Injury
Modality raw: small molecule
Modality normalized: small molecule
Target raw: etanercept
Target normalized: etanercept
NCT06706258Source recordAI-normalized
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial): A Prospective Randomized Controlled Trial
The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a single-center, randomized, controlled, single-blinded trial to determine whether perioperative intravenous administration of pantoprazole will reduce the incidence of AKI, some molecules that can be detected the urine, and major adverse kidney events (MAKE) at day 30 postoperatively, compared to famotidine after cardiac surgery. The specific aims of the study will be achieved by randomizing a group of 400 patients to receive pantoprazole (study) or famotidine (control) for 3 days perioperatively. Our study population will include any adult patients (aged over 18 years) scheduled for cardiac surgery requiring a cardiopulmonary bypass machine.
AI analysis
Indication: Acute Kidney Injury
Modality: small molecule
Target: Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Sponsor: The University of Texas Health Science Center, Houston
Source URL: ClinicalTrials.gov
Source updated: May 14, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Acute Kidney Injury
Condition normalized: Acute Kidney Injury
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Target normalized: Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
NCT01690832Source recordAI-normalized
Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial
Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury (AKI) when they undergo urgent/emergency coronary angiography. The optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI already shown to be useful for earlier diagnosis of contrast induced nephropathy. The primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention.
AI analysis
Indication: Coronary Artery Disease
Modality: small molecule
Target: standard saline infusion, fenoldopam infusion
Sponsor: University of Roma La Sapienza
Source URL: ClinicalTrials.gov
Source updated: Sep 24, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Coronary Artery Disease
Condition normalized: Coronary Artery Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: standard saline infusion, fenoldopam infusion
Target normalized: standard saline infusion, fenoldopam infusion
NCT00223509Source recordAI-normalized
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
* To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder. * To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed state of bipolar disorder
AI analysis
Indication: Bipolar Disorder
Modality: small molecule
Target: Lamotrigine
Sponsor: The University of Texas Health Science Center at San Antonio
Source URL: ClinicalTrials.gov
Source updated: Jun 20, 2012
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Bipolar Disorder
Condition normalized: Bipolar Disorder
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Lamotrigine
Target normalized: Lamotrigine
NCT03704571Source recordAI-normalized
A Predictive Model for Inadequate Bowel Preparation: Development and Validation With a Randomized Controlled Trial
We aimed to develop a predictive model of inadequate bowel preparation and to further validate it by a randomized controlled trial.
AI analysis
Indication: Bowel Preparation
Modality: small molecule
Target: Polyethylene Glycol
Sponsor: Shandong University
Source URL: ClinicalTrials.gov
Source updated: Nov 01, 2019
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Bowel Preparation
Condition normalized: Bowel Preparation
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Polyethylene Glycol
Target normalized: Polyethylene Glycol
NCT01427400Source recordAI-normalized
The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial
Breast reconstruction is a common procedure with over 86,000 breast reconstruction procedures performed in the United States in 2009. This is a 1.5-fold increase since 2007. Of these breast reconstructions, 65% use a tissue expander/implant technique. Although satisfactory results can be achieved with a single-stage technique, a two-stage approach is considered more reliable, allowing for precise positioning of the inframammary fold and an opportune time to perform a capsulotomy to increase the breast skin flap by releasing the soft tissue. The placement of the tissue expander and implant under the chest muscles is thought to minimize the incidence of capsular contracture, expander exposure, and in addition, produce acceptable aesthetic results. However, discomfort is often associated with this submuscular placement of a tissue expander or implant, specifically during the expansion phase. Patients undergoing immediate reconstruction using submuscular implants have been shown to have higher analgesic requirements and to have higher pain scores post-operatively, compared to non-reconstructed patients. An uncomfortable reconstruction can lead to under-filling of the expander, a longer expansion process, abandonment of reconstruction, and a compromised quality of life. The use of Botulinum Toxin A (Botox) injections into the chest muscles at the time of surgery may help ease the discomfort that is often associated with this procedure. The investigators propose a prospective double-blind randomized placebo-controlled trial of patients undergoing tissue expander/implant reconstruction. The information gathered from this analysis will provide a greater understanding of the effects of Botox in the setting of two-stage tissue expander/implant breast reconstruction, with the goal to improve patient satisfaction and quality of life.
AI analysis
Indication: Breast Neoplasms
Modality: small molecule
Target: Botulinum Toxin-A, Saline
Sponsor: University of British Columbia
Source URL: ClinicalTrials.gov
Source updated: Jul 29, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Skin Diseases
Condition normalized: Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Skin Diseases
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Botulinum Toxin-A, Saline
Target normalized: Botulinum Toxin-A, Saline
NCT03965533Source recordAI-normalized
A Randomised, Double-blind, Placebo-controlled Phase I Study of the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of GSK2831781 in Healthy Japanese and Caucasian Participants, and a Single Subcutaneous Dose of GSK2831781 in Healthy Caucasian Participants
This is a double-blind, placebo-controlled, randomized, parallel group, two-part study where single IV doses of GSK2831781 will be administered to healthy Japanese and Caucasian subjects in part A and SC doses will be administered to healthy Caucasian subjects in part B. GSK2831781 is a humanized, antibody-dependent cell cytotoxicity (ADCC) enhanced depleting monoclonal antibody that is specific to the lymphocyte activation gene-3 (LAG3) protein. LAG3 is a transmembrane receptor, which is upregulated on T cells following activation. The objective of the study is to assess the safety, tolerability, PK, PD and immunogenicity post administration of GSK2831781 in healthy subjects. The duration of the study is approximately 147 days for each subject enrolled. Approximately 36 subjects will be enrolled in the study, 16 subjects in Part A and 20 subjects in Part B.
AI analysis
Indication: Healthy Volunteers
Modality: small molecule
Target: GSK2831781, Placebo
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Nov 18, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Healthy Volunteers
Condition normalized: Healthy Volunteers
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GSK2831781, Placebo
Target normalized: GSK2831781, Placebo
NCT07318584Source recordAI-normalized
Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
AI analysis
Indication: E Coli Infection
Modality: small molecule
Target: Cefotetan, Carbapenems, Beta Lactam Antibiotics
Sponsor: Oregon Health and Science University
Source URL: ClinicalTrials.gov
Source updated: Jan 06, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: E Coli Infection, ESBL Producing E.Coli
Condition normalized: E Coli Infection, ESBL Producing E.Coli
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Cefotetan, Carbapenems, Beta Lactam Antibiotics
Target normalized: Cefotetan, Carbapenems, Beta Lactam Antibiotics
NCT01486706Source recordAI-normalized
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
Overactive bladder (OAB) syndrome as defined by International Continence Society is a pathological condition characterized by irritative symptoms: urinary urgency, with or without incontinence, urinary frequency and nocturia. The syndrome often seriously compromises the quality of life of the patients. The etiology of the OAB is considered multifactorial. Neural plasticity of bladder afferent pathways is one of the proposed mechanisms of OAB. The detrusor muscle itself has for many years been the target for drug treatment such as antimuscarinics. However, depression of detrusor contractility, may results in a reduced ability to empty the bladder and lead to some sympathetic adverse effects, which limits the treatment of OAB. Currently the focus of OAB treatment has changed to other bladder structures/mechanisms, such as afferent nerves and urothelial signaling as targets for intervention. C-fiber bladder afferents nerves may be critical for symptom generation in pathologic states such as OAB because these fibers demonstrate remarkable plasticity. Up-regulation of bladder C-fiber afferent nerve function may also play a role in urge incontinence, overactive bladder (OAB) and sensory urgency. The mechanism of Gabapentin's action for neuropathic pain has not been fully elucidated but is appears to have inhibitory activity on afferent C-fibers nerve activity; moreover, several studies had established the safety of Gabapentin in its treatment of different conditions. Due to the proposed mechanism, the investigators suggest that Gabapentin may be a new alternative for treating OAB.
AI analysis
Indication: Urinary Urgency
Modality: small molecule
Target: Gabapentin, Solifenacin Succinate, Placebo drugs
Sponsor: Michael E. Chua
Source URL: ClinicalTrials.gov
Source updated: Jan 02, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Urinary Urgency, Urinary Frequency, Nocturia, Incontinence, Detrusor Uninhibited Activity, Quality of Life
Condition normalized: Urinary Urgency, Urinary Frequency, Nocturia, Incontinence, Detrusor Uninhibited Activity, Quality of Life
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Gabapentin, Solifenacin Succinate, Placebo drugs
Target normalized: Gabapentin, Solifenacin Succinate, Placebo drugs
NCT02782221Source recordAI-normalized
Lipolytic Effects of GH in Human Subjects in Vivo: Molecular Mechanisms and Temporal Patterns
Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways. In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively. Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
AI analysis
Indication: Metabolic Diseases
Modality: small molecule
Target: Growth Hormone, Pegisomant
Sponsor: University of Aarhus
Source URL: ClinicalTrials.gov
Source updated: Mar 26, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Metabolic Diseases, Growth Hormone Treatment
Condition normalized: Metabolic Diseases, Growth Hormone Treatment
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Growth Hormone, Pegisomant
Target normalized: Growth Hormone, Pegisomant
NCT05134987Source recordAI-normalized
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes
NNC0363-0845 represents a novel insulin formulation aimed at improving glycemic control in patients with type 1 diabetes. The dual administration with insulin detemir allows for comparative analysis of pharmacokinetics and pharmacodynamics, potentially positioning NNC0363-0845 as a competitive alternative in the insulin market. Given the increasing prevalence of diabetes globally, successful outcomes could enhance Novo Nordisk's portfolio and market share in the diabetes care sector. The study's completion suggests readiness for further development stages, with implications for investor confidence and potential partnerships in diabetes management.
AI analysis
Indication: Diabetes Mellitus, Type 1
Modality: small molecule
Target: Insulin receptor (IR) signaling pathway, specifically targeting blood sugar-dependent insulin action.
Sponsor: Novo Nordisk A/S
Source URL: ClinicalTrials.gov
Source updated: Nov 04, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Diabetes Mellitus, Type 1
Condition normalized: Diabetes Mellitus, Type 1
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Insulin receptor (IR) signaling pathway, specifically targeting blood sugar-dependent insulin action.
Target normalized: Insulin receptor (IR) signaling pathway, specifically targeting blood sugar-dependent insulin action.
NCT01509209Source recordAI-normalized
Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial
The purpose of this study is to evaluate efficacy and safety of Cossac L tablet in the treatment of vasomotor rhinitis
AI analysis
Indication: Vasomotor Rhinitis
Modality: small molecule
Target: Pseudoephedrine / Levocetirizine
Sponsor: Hanmi Pharmaceutical Company Limited
Source URL: ClinicalTrials.gov
Source updated: May 23, 2013
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Vasomotor Rhinitis
Condition normalized: Vasomotor Rhinitis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Pseudoephedrine / Levocetirizine
Target normalized: Pseudoephedrine / Levocetirizine
NCT04508634Source recordAI-normalized
Comparison of the Clinical Efficacy of Laparoscopic Sleeve Gastrectomy and Metformin in the Treatment of Obese Patients With Polycystic Ovary Syndrome
The clinical trial compares laparoscopic sleeve gastrectomy (LSG) with metformin in treating obese patients with PCOS, a condition affecting 5% to 15% of premenopausal women. Given the rising prevalence of obesity and metabolic disorders, successful outcomes could position LSG as a viable alternative to pharmacological treatments, potentially expanding market share in obesity management. The trial's findings may influence clinical guidelines and treatment paradigms, enhancing the competitive landscape for surgical interventions in metabolic disorders. Stakeholders should monitor the trial's progress and results for implications on reimbursement and market access strategies.
AI analysis
Indication: Polycystic Ovary Syndrome
Modality: small molecule
Target: Insulin resistance and metabolic abnormalities associated with Polycystic Ovary Syndrome (PCOS)
Sponsor: Shanghai 10th People's Hospital
Source URL: ClinicalTrials.gov
Source updated: Apr 12, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Polycystic Ovary Syndrome
Condition normalized: Polycystic Ovary Syndrome
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Insulin resistance and metabolic abnormalities associated with Polycystic Ovary Syndrome (PCOS)
Target normalized: Insulin resistance and metabolic abnormalities associated with Polycystic Ovary Syndrome (PCOS)
NCT03128411Source recordAI-normalized
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
AI analysis
Indication: Leukemia, Chronic Myelogenous
Modality: small molecule
Target: Bosutinib
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: May 19, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Leukemia, Chronic Myelogenous
Condition normalized: Leukemia, Chronic Myelogenous
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Bosutinib
Target normalized: Bosutinib
NCT01734824Source recordAI-normalized
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs. This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME
AI analysis
Indication: Bone Marrow Oedema Syndrome
Modality: small molecule
Target: Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide
Sponsor: Medical University of Vienna
Source URL: ClinicalTrials.gov
Source updated: Sep 23, 2015
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Bone Marrow Oedema Syndrome, High Turnover Bone Disease, Quality of Life
Condition normalized: Bone Marrow Oedema Syndrome, High Turnover Bone Disease, Quality of Life
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide
Target normalized: Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide
NCT03923842Source recordAI-normalized
Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study
The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients
AI analysis
Indication: Nasopharyngeal Carcinoma
Modality: small molecule
Target: Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
Sponsor: Gruppo Oncologico del Nord-Ovest
Source URL: ClinicalTrials.gov
Source updated: Feb 17, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Nasopharyngeal Carcinoma, EBV Related Carcinoma
Condition normalized: Nasopharyngeal Carcinoma, EBV Related Carcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
Target normalized: Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
NCT02864784Source recordAI-normalized
A Prospective, Multicenter, Randomized, Placebo-Controlled, Two-armed, Double-blind Pilot Study to Evaluate the Safety, Tolerability and Efficacy of ACC vs. Placebo for the Treatment of Subjects With Castrate Resistant Prostate Cancer With Bone Metastasis
Amorphical Ltd.'s pilot study aims to evaluate the safety, tolerability, and efficacy of ACC in combination with standard treatments (Zoledronic Acid and Denosumab) for CRPC patients with bone metastasis. The market for CRPC therapies is significant, with increasing demand for effective adjunct treatments that can mitigate skeletal-related events (SREs) and improve patient quality of life. However, the study has been withdrawn due to budget constraints, which raises concerns about the financial viability and resource allocation of Amorphical Ltd. in advancing this asset. The competitive landscape includes established therapies like Zoledronic Acid and Denosumab, which may limit the adoption of new adjunct therapies unless compelling efficacy and safety data are presented.
AI analysis
Indication: Castrate Resistant Prostate Cancer With Bone Metastasis
Modality: small molecule
Target: Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.
Sponsor: Amorphical Ltd.
Source URL: ClinicalTrials.gov
Source updated: Feb 28, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Castrate Resistant Prostate Cancer With Bone Metastasis
Condition normalized: Castrate Resistant Prostate Cancer With Bone Metastasis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.
Target normalized: Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.
NCT04555486Source recordAI-normalized
A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
AI analysis
Indication: Primary Hyperoxaluria Type 3
Modality: small molecule
Target: DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Source URL: ClinicalTrials.gov
Source updated: Sep 19, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Primary Hyperoxaluria Type 3
Condition normalized: Primary Hyperoxaluria Type 3
Modality raw: small molecule
Modality normalized: small molecule
Target raw: DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Target normalized: DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
NCT00927459Source recordAI-normalized
A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia
This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study in male and female subjects with high cholesterol. A maximum of 32 subjects is planned for enrollment in this study.
AI analysis
Indication: Hypercholesterolemia
Modality: small molecule
Target: PRO-040201, Placebo
Sponsor: Arbutus Biopharma Corporation
Source URL: ClinicalTrials.gov
Source updated: Jan 22, 2010
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Hypercholesterolemia
Condition normalized: Hypercholesterolemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PRO-040201, Placebo
Target normalized: PRO-040201, Placebo
NCT01858935Source recordAI-normalized
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects
This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in normal, healthy, subjects
AI analysis
Indication: Healthy
Modality: small molecule
Target: ND-L02-s0201 Injection, Placebo
Sponsor: Bristol-Myers Squibb
Source URL: ClinicalTrials.gov
Source updated: May 11, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Healthy
Condition normalized: Healthy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: ND-L02-s0201 Injection, Placebo
Target normalized: ND-L02-s0201 Injection, Placebo
NCT04225715Source recordAI-normalized
A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.
AI analysis
Indication: Hepatitis B, Chronic
Modality: small molecule
Target: Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, PD-L1 LNA (RO7191863)
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Sep 19, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Hepatitis B, Chronic
Condition normalized: Hepatitis B, Chronic
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, PD-L1 LNA (RO7191863)
Target normalized: Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, PD-L1 LNA (RO7191863)
NCT06424301Source recordAI-normalized
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma (A Prospective Pilot Study)
Retinoblastoma (RB) is the most common intraocular malignancy in children, accounting for approximately 11% of all cancers diagnosed in children under the age of one. Although its incidence is relatively low-about 1 in 15,000 to 20,000 live births-RB has a high risk of intracranial metastasis via the optic nerve, often leading to poor prognosis in advanced cases. Recent advances in administration routes, such as intravitreal and intra-arterial chemotherapy, have significantly improved eye preservation rates. However, these strategies are limited by cumulative retinal toxicity and drug resistance. In refractory cases, enucleation remains the only definitive treatment to prevent extraocular spread and death. In light of these challenges, current research efforts are focused on developing novel targeted therapies that enhance anti-tumor efficacy while minimizing local toxicity. In this context, we introduce a first-in-class siRNA-based drug targeting NUDT21, which promotes tumor regression by modulating the 3'UTR tail of SMC1A, thereby suppressing tumor cell proliferation. Importantly, the siRNA drug selectively targets tumor cells, offering a favorable safety profile compared to conventional chemotherapeutic regimens. Given that both the target (NUDT21) and the mode of administration (intraocular siRNA injection) are novel in retinoblastoma treatment, there is an urgent need for early-phase investigator-initiated clinical research. This study is therefore designed to assess the short-term safety and preliminary efficacy of NUDT21 siRNA in patients with refractory retinoblastoma, and to provide an evidence base for future large-scale clinical trials.
AI analysis
Indication: Retinoblastoma
Modality: small molecule
Target: Targeting NUDT21 siRNA drugs
Sponsor: Eye & ENT Hospital of Fudan University
Source URL: ClinicalTrials.gov
Source updated: Jun 26, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Retinoblastoma, Refractory
Condition normalized: Retinoblastoma, Refractory
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Targeting NUDT21 siRNA drugs
Target normalized: Targeting NUDT21 siRNA drugs
NCT07179653Source recordAI-normalized
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.
AI analysis
Indication: HBV Infection
Modality: small molecule
Target: TVAX-008, Placebo
Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Sep 18, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: HBV Infection
Condition normalized: HBV Infection
Modality raw: small molecule
Modality normalized: small molecule
Target raw: TVAX-008, Placebo
Target normalized: TVAX-008, Placebo
NCT07080801Source recordAI-normalized
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes. In Asia, mutations in the FUS gene are relatively common among early-onset familial ALS patients. Reducing the levels of toxic FUS protein may be an effective therapeutic approach for such ALS patients without causing side effects. RAG-21 is a small interfering ribonucleic acid (siRNA) with a molecular weight of 20 kDa. Through the RNA interference mechanism, it targets the FUS gene, recognizes the corresponding mRNA, and mediates its degradation, thereby downregulating FUS gene expression and reducing toxic FUS protein levels. Accordingly, this project plans to conduct a single-center, dose-escalation clinical study aimed at evaluating the safety, tolerability, and pharmacokinetics of intrathecal bolus administration of RAG-21 in ALS patients carrying FUS gene mutations.
AI analysis
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: small molecule
Target: RAG-21
Sponsor: Beijing Tiantan Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: RAG-21
Target normalized: RAG-21
NCT04232657Source recordAI-normalized
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD). The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (\>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur \<1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.
AI analysis
Indication: Spinal Cord Injury (=3 Years)
Modality: small molecule
Target: Romosozumab, Denosumab, Placebo
Sponsor: VA Office of Research and Development
Source URL: ClinicalTrials.gov
Source updated: Apr 20, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Condition normalized: Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Romosozumab, Denosumab, Placebo
Target normalized: Romosozumab, Denosumab, Placebo
NCT04241380Source recordAI-normalized
Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection: a Randomize Multi-centers Study
Total anomalous pulmonary venous connection (TAPVC) is a complex congenital heart disease, requiring surgical repair. Pulmonary venous obstruction (PVO) is the major complication, with limited effective reinterventions and poor outcomes. This trial aims at investigating that postoperative anticoagulant management reduce the incidence of PVO.
AI analysis
Indication: Total Anomalous Pulmonary Venous Connection
Modality: small molecule
Target: Anticoagulant Solutions, No anticoagulant solutions, Anticoagulant management
Sponsor: Guangdong Provincial People's Hospital
Source URL: ClinicalTrials.gov
Source updated: Feb 19, 2020
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Total Anomalous Pulmonary Venous Connection
Condition normalized: Total Anomalous Pulmonary Venous Connection
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Anticoagulant Solutions, No anticoagulant solutions, Anticoagulant management
Target normalized: Anticoagulant Solutions, No anticoagulant solutions, Anticoagulant management
NCT00852423Source recordAI-normalized
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria
Malaria is the most important human parasitic disease and is responsible of high morbidity and mortality in resource-poor countries. Pregnant women, who are a high-risk group, are almost always excluded from clinical trials; thus, the investigators lack sufficient information on the safety and efficacy of most antimalarials in pregnancy. The recommendation of the World Health Organization to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries, however documentation of their efficacy and safety in pregnancy is still limited. Thus, the investigators propose to evaluate the efficacy and safety of 4 ACT(artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), when used to treat pregnant women with P. falciparum malaria; the results will help to recommend the optimal therapy for this high-risk group in Africa.
AI analysis
Indication: Malaria in Pregnancy
Modality: small molecule
Target: Dihydroartemisinin-piperaquine, Artesunate-mefloquine, Artesunate-amodiaquine, Artemether-lumefantrine
Sponsor: Institute of Tropical Medicine, Belgium
Source URL: ClinicalTrials.gov
Source updated: Mar 14, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Malaria in Pregnancy
Condition normalized: Malaria in Pregnancy
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dihydroartemisinin-piperaquine, Artesunate-mefloquine, Artesunate-amodiaquine, Artemether-lumefantrine
Target normalized: Dihydroartemisinin-piperaquine, Artesunate-mefloquine, Artesunate-amodiaquine, Artemether-lumefantrine
NCT01578655Source recordAI-normalized
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
This Phase 3 study has been designed to confirm that adding custirsen to cabazitaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/prednisone treatment in men with metastatic castrate resistant prostate cancer (CRPC). This will be a randomized, open-label, multicenter, international trial. Treatment will consist of cabazitaxel/prednisone/custirsen vs. cabazitaxel/prednisone. A total of approximately 630 patients will be randomized with equal probability to the two arms.
AI analysis
Indication: Prostate Cancer
Modality: small molecule
Target: cabazitaxel, prednisone, custirsen sodium
Sponsor: Achieve Life Sciences
Source URL: ClinicalTrials.gov
Source updated: Oct 12, 2016
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Prostate Cancer
Condition normalized: Prostate Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: cabazitaxel, prednisone, custirsen sodium
Target normalized: cabazitaxel, prednisone, custirsen sodium
NCT00158548Source recordAI-normalized
Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
AI analysis
Indication: Malaria
Modality: small molecule
Target: SP, chloroquine, amodiaquine, primaquine, artesunate
Sponsor: London School of Hygiene and Tropical Medicine
Source URL: ClinicalTrials.gov
Source updated: Jan 12, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Malaria, Falciparum Malaria, Vivax Malaria
Condition normalized: Malaria, Falciparum Malaria, Vivax Malaria
Modality raw: small molecule
Modality normalized: small molecule
Target raw: SP, chloroquine, amodiaquine, primaquine, artesunate
Target normalized: SP, chloroquine, amodiaquine, primaquine, artesunate
NCT00106028Source recordAI-normalized
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There are no approved drugs for the treatment of OI in children, even though some intravenous (IV) bisphosphonates are used off-label in some countries. In a single dose, pharmacokinetic study, data showed that risedronate was well tolerated in 28 children with OI. This three year study will test the safety and efficacy of risedronate in the treatment of children with OI. For the first year, patients will be randomized to the risedronate and placebo groups in a 2:1 ratio. For the second and third years of the study, all patients will receive risedronate.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: small molecule
Target: risedronate sodium (Actonel), Placebo
Sponsor: Warner Chilcott
Source URL: ClinicalTrials.gov
Source updated: Apr 22, 2013
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: small molecule
Modality normalized: small molecule
Target raw: risedronate sodium (Actonel), Placebo
Target normalized: risedronate sodium (Actonel), Placebo
NCT07557446Source recordAI-normalized
A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
AI analysis
Indication: Osteogenesis Imperfecta (OI)
Modality: small molecule
Target: AGA2115
Sponsor: Angitia Biopharmaceuticals Guangzhou Limited
Source URL: ClinicalTrials.gov
Source updated: Apr 29, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Osteogenesis Imperfecta (OI)
Condition normalized: Osteogenesis Imperfecta (OI)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: AGA2115
Target normalized: AGA2115
NCT06632418Source recordAI-normalized
A Randomized Controlled Trial Evaluating the Safety and Feasibility of the Recombinant Human Platelet-derived Growth Factor B (rhPDGF-BB)-Enhanced Collagen Plug for Complex Perianal Fistula Healing
The average success rate for healing and remission of complex perianal fistulas, idiopathic or Crohn's-related, is approximately 50%. These abnormal connections between the rectum and the outside skin remain a major clinical challenge in need of new treatments aimed at tissue repair. Platelet-derived growth factor drives wound healing and tissue regeneration, and manufactured PDGF is currently used to heal diabetic foot ulcers and regenerate bone in periodontal and orthopedic patients. Manufactured recombinant human PDGF has the potential to improve the success rate for complete healing of complex perianal fistulas, reduce the recurrence rate due to reopening of the fistula tract, and avoid complications associated with routine surgical interventions.
AI analysis
Indication: Anal Fistula
Modality: small molecule
Target: RhPDGF-BB
Sponsor: Alexander Hawkins
Source URL: ClinicalTrials.gov
Source updated: Jan 21, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Anal Fistula, Complex Perianal Fistula
Condition normalized: Anal Fistula, Complex Perianal Fistula
Modality raw: small molecule
Modality normalized: small molecule
Target raw: RhPDGF-BB
Target normalized: RhPDGF-BB
NCT03216486Source recordAI-normalized
A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: small molecule
Target: BPS804
Sponsor: Ultragenyx Pharmaceutical Inc
Source URL: ClinicalTrials.gov
Source updated: Jul 03, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: small molecule
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BPS804
Target normalized: BPS804